Cancer-associated_cachexia

Exploring the potential of ginseng-derived compounds in treating cancer cachexia.

Cancer cachexia is a complex wasting syndrome characterized by significant loss of body weight and muscle mass in patients with advanced cancer. The disease is associated with increased systemic inflammation, altered neurohormonal signaling, and, in particular, an increased catabolic rate...

🗓️ 2025-11-21
📰 Publication: Journal Of Ginseng Research
Read MoreExploring the potential of ginseng-derived compounds in treating cancer cachexia.

Revisiting Cancer Cachexia Staging: Introducing an "At Risk" Category Based on AWGC Components.

Cancer cachexia is a multifactorial syndrome characterized by progressive weight loss, muscle wasting, and systemic inflammation. Early identification of individuals at risk for cachexia is essential for timely intervention, yet a universally accepted definition of the "at risk" stage remains...

🗓️ 2025-11-20
📰 Publication: Thoracic Cancer
Read MoreRevisiting Cancer Cachexia Staging: Introducing an "At Risk" Category Based on AWGC Components.

The canonical ER stress IRE1α/XBP1 pathway mediates skeletal muscle wasting during pancreatic cancer cachexia.

Cancer cachexia is a debilitating syndrome characterized by the progressive loss of skeletal muscle mass with or without fat loss. Recent studies have implicated dysregulation of the endoplasmic reticulum (ER) stress-induced unfolded protein response (UPR) pathways in skeletal muscle under...

🗓️ 2025-11-18
📰 Publication: Embo Molecular Medicine
Read MoreThe canonical ER stress IRE1α/XBP1 pathway mediates skeletal muscle wasting during pancreatic cancer cachexia.

Impaired cAMP-PKA-CREB1 signalling drives mitochondrial dysfunction in skeletal muscle during cancer cachexia.

Skeletal muscle wasting is a defining feature of cancer cachexia, a multifactorial syndrome that drastically compromises patient quality of life and treatment outcomes. Mitochondrial dysfunction is a major contributor to skeletal muscle wasting in cancer cachexia, yet the upstream molecular...

🗓️ 2025-11-13
Read MoreImpaired cAMP-PKA-CREB1 signalling drives mitochondrial dysfunction in skeletal muscle during cancer cachexia.

Advancements of investigational agents for cancer cachexia: what clinical progress have we seen in the last 5 years?

INTRODUCTION

Cancer cachexia is a multifactorial syndrome affecting up to 80% of advanced cancer patients, associated with poor quality of life, increased cancer-treatment toxicity, and reduced survival. Despite its clinical burden, no FDA- or EMA-approved pharmacologic therapies currently exist.

AREAS COVERED

This review...

🗓️ 2025-11-12
📰 Publication: Expert Opinion On Investigational Drugs
Read MoreAdvancements of investigational agents for cancer cachexia: what clinical progress have we seen in the last 5 years?

A Creatinine-CAR Composite Index (CCAR) Optimized by Machine Learning for Prognosis in Cancer Cachexia.

BACKGROUND

Cancer cachexia is a multifactorial syndrome associated with poor prognosis and impaired quality of life in cancer patients. However, survival prediction in cancer cachexia remains difficult due to the lack of reliable biomarkers.

METHODS

This retrospective cohort study analysed data from 1,367...

🗓️ 2025-11-11
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreA Creatinine-CAR Composite Index (CCAR) Optimized by Machine Learning for Prognosis in Cancer Cachexia.

Efficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial.

BACKGROUND

Anamorelin, a ghrelin receptor agonist, has shown efficacy in lung cancer cachexia. We conducted the first randomized controlled trial to evaluate its effects in gastric cancer cachexia.

METHODS

In this multicenter, open-label randomized controlled trial conducted across 10 hospitals in Japan, patients...

🗓️ 2025-11-03
📰 Publication: Eclinicalmedicine
Read MoreEfficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial.

Transcriptional landscape of skeletal muscle in cancer patients.

Bhatt et al. have identified two RNAome-based skeletal muscle subtypes in cancer cachexia. The first subtype is cachexia associated with weight and muscle loss, fiber atrophy, and shortened survival. Furthermore, this subtype has dysregulated post-transcriptional networks involving hub long noncoding...

🗓️ 2025-11-02
📰 Publication: Trends In Molecular Medicine
Read MoreTranscriptional landscape of skeletal muscle in cancer patients.

Pancreatic Damage in Ovarian Cancer-Associated Cachexia Is Driven by Activin A Signalling.

BACKGROUND

Cancer-associated cachexia (CAC) is a severe metabolic disorder characterized by involuntary weight loss, skeletal muscle atrophy and adipose tissue depletion. It is a major contributor to morbidity and mortality in the advanced stages of various cancers. However, the impact of...

🗓️ 2025-10-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MorePancreatic Damage in Ovarian Cancer-Associated Cachexia Is Driven by Activin A Signalling.

New models for cancer cachexia and their application to drug discovery.

Cancer cachexia (CC) is a multifactorial syndrome characterized by progressive weight loss, anorexia, and loss of skeletal muscle and fat mass, resulting in reduced quality of life and poor prognosis. Currently, there are no approved pharmacological treatments for CC, highlighting...

🗓️ 2025-10-03
📰 Publication: Expert Opinion On Drug Discovery
Read MoreNew models for cancer cachexia and their application to drug discovery.

Cachexia progression differs among mouse models of metastatic triple-negative breast cancer.

Cancer-associated cachexia decreases quality of life, reduces therapy response, and diminishes survival prospects. Effective cachexia countermeasures remain a significant unmet need. Research into cancer cachexia has made extensive use of models of colon, lung and pancreatic cancers. However, while cachexia...

🗓️ 2025-10-03
📰 Publication: American Journal Of Physiology-Cell Physiology
Read MoreCachexia progression differs among mouse models of metastatic triple-negative breast cancer.

Vagal blockade of the brain-liver axis deters cancer-associated cachexia.

Cancer-associated cachexia (CAC) is a multifactorial and currently incurable syndrome responsible for nearly one-third of cancer-related deaths. It contributes to therapy resistance and increases mortality among affected patients. In this study, we show that cancer-induced systemic inflammation alters vagal tone...

🗓️ 2025-07-29
📰 Publication: Cell
Read MoreVagal blockade of the brain-liver axis deters cancer-associated cachexia.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!